Xenomics, Inc. (XNOM)
Interview with: Dr. Randy White, CEO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their DNA-based urine tests for tumor detection and monitoring; tissue transplantation; infectious disease; forensic identity; drug development and bioterrorism.

Cover Story

CEOCFO Interview Index

CEOCFO Current Issue

Cover Story Archives

Future Features

Analyst Interviews

Corporate Financials

Archived Interviews
 
About CEOCFOinterviews.com

Contact & Ordering

This is a printer friendly page!

Xenomics is offering a near term, safe and non-invasive technology for women who need prenatal genetic testing that may be two thirds the cost of the amniocentesis procedure currently on the market



Healthcare
Biotechnology
(XNOM-OTC: BB)

Xenomics, Inc.





Dr. Randy White
Chief Executive Officer

Interview conducted by:
Lynn Fosse, Senior Editor

CEOCFOinterviews.com
December 2004

To order the complete December 2, 2004 Issue of CEOCFOinterviews.com left click below for our secure forms:

Purchase NOW!

There is a $5.00 charge for each current issue!

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

When I heard about Xenomics, I drew an assignment to do a technology assessment and my first thoughts were ‘great, another genomics company, just what the world needs’. When I got here and looked under the hood at the engine and saw the breadth and the depth of this technology, the one thing that was inescapable was that Xenomics creates new markets that are today not molecular and those new markets are at least double if not triple the size of the existing size of the market.” - Dr. Randy White

Newsflash!

To view Releases highlight & left click on the company name!